Psychedelic ETF

No spam. We promise


Mental illnesses are on the rise and existing medications have been found wanting. A staggering 30% of depression patients do not respond to any currently available treatment.1 Research budgets for psychiatric medicine in large companies have fallen dramatically over the last decade, as confidence wanes that more investment in the same direction will produce improved results.2

Recent breakthrough studies in the medical repurposing of psychedelics and ketamine have found significant benefits to sufferers of anxiety, PTSD, OCD, eating disorders, depression and others. Declared a “breakthrough therapy,” by the FDA in 2018 and 2019, studies on the use of psilocybin have found rapid, marked, and enduring anti-anxiety and depression effects.

Invest in the Future of Psychedelics and Medical Cannabis

PSY is the first US-listed psychedelic ETF. It seeks to track the BITA Medical Psychedelics, Cannabis, and Ketamine Index, a rules-based index that tracks the performance of companies, listed in North American Exchanges, that operate business models focused on the usage of Psychedelics and Medical Cannabis for medicinal and health treatment purposes. It is a weighted, rules-based index that has the potential to mitigate risk of over-exposure to any single company.

Companies included in the index must have a minimum market capitalization of $75 million, and operate in the production, distribution, or services related to medical psychedelics, medical cannabis or other medicinal drugs and their derivatives.

1 “Compass Pathways (NASDAQ:CMPS) IPO Proves Psychedelic Medicine Investment Thesis, WPSS Investments Newswire,” October 1, 2020. https://www.globenewswire.com/news-release/2020/10/02/2102708/0/en/compass-pathways-nasdaq-cmps-ipo-proves-psyche%c2%acdelic-medicine-investment-thesis.html

2 “Big pharma pulling back from mental health drug research: studies,” October 29, 2012, https://www.ctvnews.ca/health/health-headlines/big-pharma-pulling-back-from-mental-health-drug-research-studies-1.1015154

Fund Data and Pricing

Net Assets $3.45M
Premium/discount 0.26%
NAV $27.61
Closing Price $27.68
Shares Outstanding 125,000
Median 30 Day Spread 0.41%
Data as of 06/11/2021

Fund Details

Fund inception 05/27/21
Ticker PSY
Primary Exchange NYSE
CUSIP 26922B808
Fund Holdings 20
Expense Ratio 0.75%
30 Day SEC Yield* n/a
* Yield as of
YTD 1 Months 3 Months 6 Months 1 Year Since Inception
Total Return (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% 3.86%
Market Price (%) xx.xx% xx.xx% xx.xx% xx.xx% xx.xx% 4.00%
1 Year Since Inception
Total Return (%) xx.xx% xx.xx%
Market Price (%) xx.xx% xx.xx%
The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 833.333.9383. Short term performance, in particular, is not a good indication of the fund’s future performance, and an investment should not be made based solely on returns. Market price is the price at which shares in the ETF can be brought or sold on the exchanges during trading hours, while the net asset value (NAV) represents the value of each share’s portion of the fund’s underlying assets and cash at the end of the trading day.
Name Symbol Stock price % Net assets Shares Held Market Value
Aurora Cannabis Inc ACB CN $11.94 7.10% 39,896 392,210
Charlottes Web Holdings Inc CWEB CN $5.35 6.60% 82,720 364,375
Cronos Group Inc CRON CN $10.82 6.10% 37,808 336,818
Mind Medicine Mindmed Inc MNMD $3.92 6.05% 85,200 333,984
Compass Pathways Plc CMPS $39.68 5.85% 8,136 322,836
Corbus Pharmaceuticals Hldgs I Com CRBP $2.18 5.73% 145,096 316,309
Zynerba Pharmaceuticals Inc ZYNE $5.64 5.25% 51,376 289,761
Supreme Cannabis Co Int/the FIRE CN $0.355 5.21% 984,000 287,613
Cbdmd Inc YCBD $3.4 5.00% 81,216 276,134
Numinus Wellness Inc NUMI CN $1.03 4.91% 320,000 271,376
Data as of 06/14/2021. Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.
View full holdings
Download Fund Documents
Investment Case
Fact Sheet
Index Methodology Guide
Summary Prospectus

Reasons to Invest

Psychedelic future

Imagine if a non-addictive, short term intervention with minimal side effects could dramatically improve mental health? Psychedelics could be a part of such treatment.

Next Gen. Medicine

Psychedelics promote neural plasticity, essentially allowing the brain to rewire itself. Recipients report unparalleled insight and paradigm shifts akin to mystical or spiritual awakenings.

Growth Potential

Psilocybin, LSD and their derivatives could become an integral part of the multi-billion dollar global medicine market; offering hope to many whose conditions seem untreatable in current paradigms.


PSY also offers exposure to companies leading the medical repurposing of cannabis, to treat chronic pain, symptoms of MS, and side effects of chemotherapy among others.